Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NCI 12CC11

Title
Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial
Principal Investigator
Brian Hitsman
Details
  • Status: Accepting New Patients
  • Study Type: Supportive Care, Treatment
  • Protocol No:.NCI 12CC11
Purpose
The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.
Overview
This study is for cancer patients who are smokers and who have expressed an interest in quitting. There are a number of drugs on the market that help patients with their dependence on nicotine (the active drug in tobacco). Research suggests that, while these drugs can be effective for some individuals, helping patients to deal with stress and other psychological issues associated with quitting smoking is important. This study combines counseling and the drug varenicline to combat both the psychological and the physical dependence on nicotine. The counseling that all participants will receive is consistent with clinical treatment guidelines for smoking cessation. The study drug (varenicline) is FDA approved for both 12-week and 24-week treatment durations for smoking cessation. This study will be comparing the effectiveness of the two varenicline treatment durations (12 or 24 weeks), and both groups will also receive 24 weeks of counseling. Participants will receive all counseling and medication at no charge and will be compensated for travel.
Eligibility
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older.
  • Participants must have a cancer diagnosis (all cancer sites eligible) within the past 5 years.
  • Participants must identify themselves as current smokers.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Study participants will be randomized to one of two treatment groups. Participants in group 1 will get counseling + 24 weeks of active study drug pills. Participants in group 2 will get counseling + 12 weeks of active study drug pills followed by 12 weeks of placebo pills.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

last updated: 22-Aug-14 08:34 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.